Population-based study of DNA image cytometry as screening method for esophageal cancer

Lin Zhao, Wen-Qiang Wei, De-Li Zhao, Chang-Qing Hao, Dong-Mei Lin, Qin-Jing Pan, Xin-Qing Li, Fu-Hua Lei, Jin-Wu Wang, Guo-Qing Wang, Qi Shang, You-Lin Qiao

METHODS: This study was designed as a population-based screening study. A total of 582 local residents aged 40 years-69 years were recruited from Linzhou in Henan and Feicheng in Shandong. However, only 452 subjects had results of liquid-based cytology, DNA-ICM and pathology. The sensitivity and specificity of DNA-ICM were calculated and compared with liquid-based cytology in moderate dysplasia or worse.

RESULTS: Sensitivities of DNA-ICM ranging from at least 1 to 4 aneuploid cells were 90.91%, 86.36%, 79.55% and 77.27%, respectively, which were better than that of liquid-based cytology (75%). Specificities of DNA-ICM were 70.83%, 84.07%, 92.65% and 96.81%, but the specificity of liquid-based cytology was 91.91%. The sensitivity and specificity of a combination of liquid-based cytology and DNA-ICM were 84.09% and 85.78%, respectively.

CONCLUSION: It is possible to use DNA-ICM technique as a primary screening method for esophageal squamous precancerous lesions.

© 2012 Baishideng. All rights reserved.

Key words: DNA image cytometry; Aneuploidy; Screening; Esophageal cancer; Precancerous lesions

Peer reviewers: Hiroyuki Uehara, MD, PhD, Chief, Division of Pancreatologia, Department of Gastroenterology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari, Osaka 537-8511, Japan; Joong-Won Park, MD, PhD, Center for Liver Cancer, National Cancer Center, 111 Jungbalsan-ro, Iksan-dong, Goyang, Gyeonggi 410-769, South Korea; Kazuaki Takabe, MD, PhD, Assistant Professor of Surgery and Assistant Professor of Biochemistry and Molecular Biology, Surgical Oncology, VCU Massey Cancer Center, Virginia Commonwealth University/Medical College of Virginia, PO Box 980011, Richmond VA 23298-0011, United States
Zhao L, Wei WQ, Zhao DL, Hao CQ, Lin DM, Pan QJ, Li XQ, Lei FH, Wang JW, Wang GQ, Shang Q, Qiao YL. Population-based study of DNA image cytometry as screening method for esophageal cancer. World J Gastroenterol 2012; 18(4): 375-382. Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i4/375.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i4.375

INTRODUCTION

Esophageal cancer, the world’s eighth most common cancer, is curable if detected early. In China, the survival rates are over 85% when found at an early stage of esophageal squamous cell carcinoma (ESCC), but less than 10% when diagnosed at the advanced stage[1]. Patients in early stages are asymptomatic, and therefore, screening is important for detecting patients before they progress to advanced stage disease.

Presently, several screening methods have been explored in high-risk areas of China including conventional cytology[2-5], liquid-based cytology[6], occult blood detection[11-13] and endoscopic biopsy examination with Lugol’s iodine staining[9]. Conventional cytology had been used in high-risk areas of China in the 1970s, but it has been replaced by liquid-based cytology. Occult blood detection has been explored in several areas in China, but because of low sensitivity and specificity, this method has not been used widely yet. Endoscopic examination with Lugol’s iodine staining is mostly used in high-risk areas in China. Although endoscopic examination with Lugol iodine staining has high sensitivity and specificity of more than 90%, because of the high cost, this screening method is difficult to be accepted by residents in rural high-risk areas. Meanwhile, endoscopic and pathological doctors require a lengthy qualification process. Liquid-based cytology may improve the quality of the cytological procedure and provide satisfactory diagnostic slides compared with conventional cytology, but it has limits for improving the sensitivity and specificity of screening[6,9]. Furthermore, there is a skill shortage in rural high-risk areas due to the lack of experienced cytologists.

DNA image cytometry (DNA-ICM) has been proposed as a simple, easy, sensitive and high specificity method for screening of ESCC. Changes in DNA ploidy occurring in human tumors have been shown to be a global reflection of the chromosomal and subchromosomal genetic changes which are important in tumor development and progression[14-16]. DNA ploidy is analyzed by DNA-ICM as a screening marker to reveal the development of ESCC. Until now, few studies have investigated the relationship between DNA ploidy and ESCC diagnosis application[16,18]. In these previous studies, researchers obtained specimens from surgical tissue, paraffin-embedded tissue and endoscopic biopsy. They have analyzed the prognostic value of DNA ploidy in the progression of ESCC, and predicted the prognosis of ESCC. Furthermore, these studies have not been performed by a population-based method, but were small sample clinical studies. DNA-ICM has been used as a screening method in cervical cancer[14], and was shown to have a higher sensitivity than that of cytology. However, no population-based screening study has focused on DNA-ICM for assessment of esophageal squamous carcinoma and precancerous lesions.

In order to evaluate sensitivity and specificity of ESCC screening by DNA-ICM, we conducted a population-based study in two high-risk areas of China.

MATERIALS AND METHODS

Study design and subjects recruitment

This was a population-based screening study. In two areas at high risk of ESCC, namely Linzhou in Henan province and Feicheng in Shandong province, local trained village doctors visited every family in June 2010, gathered local residents to the village hospital, and then explained this study to them. Finally, 70% of the local residents consented to participate in our study. Inclusion criteria were: (1) local resident; (2) age 40 to 69 years; (3) no contraindications for endoscopic examinations (e.g., history of reaction to iodine or lidocaine, serious cardiovascular disease, poor health status); and (4) voluntarily consenting to participate in screening and signing the informed consent document. Exclusion criteria were: participants who had a history of liver cirrhosis, esophageal varices, hematemesis, a bleeding disorder, uncontrolled congestive heart failure, unstable angina or a reaction to topical anesthetics or iodine.

The details of subject recruitment and exclusion, those with cytology and endoscopy examinations, and the study procedure are described in Figure 1.

This study was approved by the Institutional Review Board of Shandong Medical College附属医院. The study protocol was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院. This study was approved by the Institutional Review Board of Shandong Medical College附属医院.
Boards of the Cancer Institute/Hospital of the Chinese Academy of Medical Sciences (CICAMS) and Peking Union Medical College.

Cytological sample collection
Preparation for balloon examination: All cytological examinations were performed in the villages. After completing informed consent and a short questionnaire, patients fasted overnight prior to examination. Before balloon examination, an inflatable balloon was soaked in 75% alcohol for at least 12 h.

Collection of cytological samples: Balloon examination was performed by an experienced local doctor. After cleansing the oral cavity, the balloon was inserted into the back of the throat and swallowed by the patient. Once in the stomach, the balloon and covering mesh were expanded and then gradually pulled up the esophagus. When the balloon reached the upper esophageal sphincter, it was deflated and withdrawn completely. After removal, the balloon was placed in a 50 mL centrifuge tube including Thinprep digestive fluid, the catheter was cut off, and the centrifuge tube was sealed and transferred to a CICAMS laboratory.

Reparation of cytological slides: Each sample was vortexed for 10 min to remove adherent cells from the balloon, which was then taken out of the tube. The remaining cell suspension was centrifuged at 2500 r/min for 5 min. Excess supernatant was discarded and the cell deposits remained in the tube. All cell deposits were then transferred to Eppendorf tubes, which included 20 mL of Thinprep preserving cyto-solution. Every sample in the eppendorf tube was prepared for two cytological slides. Every subject had two slides, which were divided randomly for a Pap smear or Feulgen staining. We adopted a crossover design to eliminate the impact of numbers of cells on the diagnosis.

The slides were reviewed by two cytopathologists independently, and discrepancies were adjudicated by joint review. The slides were read blindly without the pathological results. Diagnostic criteria were adapted from criteria of the original Bethesda System.

DNA image analysis on liquid-based specimens
The specimens were stained by the Feulgen-Thionin method as detailed in one previous study. The hardware of the system included a MOTIC BA600 microscope, DELL370 workstation, automated microscope control-box, Moticam 1501 camera and assistant accessories. The software for the DNA-ICM system came from Canada.

This system automatically loaded each slide, scanned the areas of Thinprep deposition, stored an image of every object detected, calculated a set of 132 features for each cell nucleus, ordered the DNA content of the nucleus, and used multilevel decision-making to classify each object as either nucleus or ‘junk’. Finally, two cytopathologists checked blindly the image of every nucleus repeatedly, then excluded an unsatisfactory nucleus. Figure 2 shows the interface of DNA-ICM which is used to
assess the image of the cell nucleus with its corresponding features.

At least 400 normal epithelial cells were taken as the internal reference diploid population in each specimen. The coefficient of variation (CV) of the DNA quantity of these reference cells never exceeded 3%. This value was lower than the CV of 5% recommended by the European Society for Analytical Cellular Pathology (ESAPC).

The quality control process was implemented and depended on the reports of ESAPC.

DNA index = DNA IOD value of detected cell/Av.

RESULTS

Subject demographics

The study consisted of 452 subjects, including 171 men and 281 women. The mean age of the participants was 55 years (range, 40-69 years). Overall, 60 subjects (13.3%) came from Linzhou in Henan province and 392 subjects (86.7%) from Feicheng in Shandong province. The analytic database was limited to 452 subjects who had results of liquid-based cytology, histopathology and DNA-ICM.

Results of histopathology, liquid-based cytology and DNA-ICM

There were 336 of 452 (74.3%) subjects with “negative” histology, 10 (2.2%) had severe dysplasia, 29 (6.4%) had moderate dysplasia, 72 (15.9%) had mild dysplasia and 5 (1.1%) were diagnosed with ESCC. For diagnoses with liquid-based cytology, 386 subjects were normal (85.4%) and 66 (14.6%) had cytological abnormalities, of which 39 had atypical squamous cells of undetermined significance (ASCUS), 19 had low-grade squamous intraepithelial lesion (LSIL), 3 had high grade squamous intraepithelial lesion (HSIL) and 5 cases had ESCC. For DNA-ICM, 293 of 452 (64.8%) subjects had no aneuploid cells, and 66 (14.6%) subjects had aneuploid cells.

Table 1 shows diploid cells and aneuploidy classified by pathological diagnoses. The results showed that 27.4% of

| Pathological diagnoses | Normal | mD | MD | SD | ESCC |
|------------------------|--------|----|----|----|------|
| Diploid                | 244 (72.6) | 45 (12.5) | 4 (13.8) | 0 (0) | 0 (0) |
| Aneuploid              | 92 (27.4) | 27 (7.5) | 25 (86.2) | 10 (100) | 5 (100) |
| No. of aneuploid cells ≤ 5 | 90 (26.8) | 25 (34.7) | 7 (24.1) | 1 (10) | 0 (0) |
| No. of aneuploid cells ≤ 10 | 2 (0.6) | 2 (2.8) | 2 (6.9) | 2 (20) | 0 (0) |
| No. of aneuploid cells ≤ 20 | 0 (0) | 0 (0) | 8 (27.6) | 5 (50) | 2 (40) |
| No. of aneuploid cells > 20 | 0 (0) | 0 (0) | 8 (27.6) | 2 (20) | 3 (60) |
| Total                  | 336 | 72 | 29 | 10 | 5 |

mD: Mild dysplasia; MD: Moderate dysplasia; SD: Severe dysplasia; ESCC: Esophageal squamous cell carcinoma.

Zhao L et al. DNA image cytometry screening esophageal cancer
subjects with normal esophageal epithelia presented with aneuploid cells, but the proportions of aneuploid cells for subjects with mild dysplasia, moderate dysplasia, severe dysplasia, and ESCC were 37.5%, 86.2%, 100% and 100%, respectively. In particular, among subjects with severe dysplasia or ESCC, the proportion of diploid cells was zero. Furthermore, the larger the proportion of aneuploid cells, the worse the lesions.

**The sensitivity and specificity of DNA-ICM compared with histopathology and were showed in ROC curve**

Figure 3 shows receiver operating characteristics curves of the DNA-ICM method based on mild dysplasia or worse, moderate dysplasia or worse and severe dysplasia or worse. It also shows the sensitivity and specificity of DNA ploidy by category, which is the minimum number of cells required to define a subject as aneuploid. It is difficult to determine the exact threshold value, so optimal limits of the threshold for DNA-ICM method were determined. According to Figure 3, the optimal values for sensitivity and specificity fell around a minimum number of aneuploid cells ranging from at least 1 to 5.

**Comparison of liquid-based cytology and DNA-ICM**

Table 2 shows the sensitivity, specificity, PPV and NPV of liquid-based cytology and DNA-ICM in our laboratory using these samples as determined by two blinded reviewers. ASCUS, LSIL and HSIL thresholds for cytology, and 1-5 aneuploid cells present at a DNA index of 2.5 for ploidy. For the threshold of moderate dysplasia or worse, sensitivities of the DNA-ICM method ranging from at least 1 aneuploid cell to 4 aneuploid cells were 90.91%, 86.36%, 79.55% and 77.27%, respectively. The specificities were 70.83%, 84.07%, 92.65% and 96.81%, respectively, but the sensitivity and specificity of liquid-based cytology for ASCUS or worse was 75% and 91.91%, respectively.

**Combined liquid-based cytology with DNA ploidy**

Table 3 shows the sensitivity and specificity of a combination of liquid-based cytology and DNA-ICM. Liquid-based cytology took ASCUS as the threshold value. The threshold value of DNA-ICM ranged from at least 1 aneuploid cell to at least 5 aneuploid cells. The combination improved sensitivity and the ability to screen for positive cases. The group “≥ ASCUS or ≥ 3 aneuploid cells” delivered optimal sensitivity and specificity, 84.09% and 85.78%, respectively.

**DISCUSSION**

This is the first population-based study to explore DNA image analysis technology as a screening method in ESCC. Our study indicated that the higher the grade of esophageal precancerous lesions the higher the proportion of aneuploid cells. This result is similar to the conclusion that early malignant changes in the esophagus are associated with alterations in DNA content in the clinical study by Blant et al.[13] in Switzerland. Therefore, DNA image analysis may have potential clinical application as a screening method for ESCC.

Our study also showed that the sensitivities of the
DNA-ICM method ranging from at least 1 aneuploid cell to 4 aneuploid cells were 90.91%, 86.36%, 79.55% and 77.27%, respectively, in identifying moderate dysplasia or worse disease. These sensitivities were much higher than that of liquid-based cytological testing (75%) using moderate dysplasia or worse as the threshold.

One study on cervical cancer showed that the sensitivity of DNA cytometry testing for cervical cancer was 91.7%, whereas the sensitivity of cytological testing was 44.5%, and the specificity was 54.1% for DNA cytometry testing and 70.6% for cytological testing. Singh et al proposed the idea of combination screening using the DNA-ICM method, and in cervical cancer, human papillomavirus screening with cytology would be an optimal method to detect progressive lesions with the greatest possible sensitivity and specificity. In our study, the aim of combining liquid-based cytology and DNA-ICM was to explore whether the combination could improve the sensitivity in screening for ESCC and precancerous lesions. The results indicated that the group "≥ ASCUS or ≥ 3 aneuploid cells" had the optimal sensitivity (84.09%) and specificity (85.78%). This improved the sensitivity of liquid-based cytological testing (75%) based on moderate dysplasia or worse. However, the specificities of combined cytology and DNA-ICM were lower than for the individual methodologies. If both the results of cytology and DNA-ICM are negative, the specificities of the combination were negative. This led to the low specificities. All in all, a combination of the two methods was only an indication for screening, and was not suitable for screening ESCC and precancerous lesions.

It is important to note one parameter of DNA-ICM in this study: the DNA index. In this study, we took the 5c value as the threshold value of the aneuploid cell. The ESAPC suggest that 5c is the cut-off value for aneuploidy. A few studies suggested the threshold value for aneuploidy in other cancers was 5c, based on clinical samples. DNA-ICM, used in cervical cancer screening, also set 5c as the cut-off value since results had showed that optimal values for sensitivity and specificity fell around a DNA ploidy of 5c. However, this value has not been verified in esophageal cancer screening. It may be a limitation of our study, and future studies should confirm the cut-off value of DNA-ICM in esophageal cancer.

Our study is also the first study using cytological samples for DNA-ICM with Feulgen staining by inflatable balloon. Previous studies on esophageal cancer and DNA-ICM collected biopsy specimens and then analyzed the DNA content of the nucleus. The sample collection procedure in our study was simple, and easy to perform as a screening method. Most ESCC cases occur in rural areas in China where residents have little knowledge of the capacity of medical diagnosis, and there is little health education and inadequate treatment. These areas also lack experienced cytopathologists and pathologists, as medical training is arduous and long. However, for DNA-ICM, a technician could work independently after 3 wk training, and 90% of slides could be diagnosed in 1 min, so this method would be easier to perform. Cytological diagnosis depends largely on the numbers of cytopathologists, but DNA-ICM is more objective as it is read by computer. Our aim was to explore DNA-ICM as a primary screening method, which is certain to miss some positive cases compared with the “golden standard” of endoscopic examination. Nevertheless, we should not ignore the advantages of DNA-ICM: it is simple, objective, and likely to be accepted by participants. According to the data analysis of 116 subjects with mild dysplasia or worse, 49 results of DNA-ICM were negative (false negative rate 42.2%). However, all of the 49 cases (100%) had mild or moderate dysplasia. This means that no advanced stage esophageal lesions had been missed. We also have relevant data about the efficiency of cell collection by inflatable balloon. It is the so-called adequacy codes are classified into three grades: adequate for evaluation; satisfactory for evaluation but limited; and unsatisfactory.

The number of subjects with adequate for evaluation cytological samples was 288, which is 63.7% of all subjects; with satisfactory for evaluation but limited samples was 163 (36.1%), and the sample of one subject was unsatisfactory (0.2%). Thus, we could say that the efficiency of cell collection by inflatable balloon was good for diagnosis by DNA-ICM.

DNA-ICM could also be used to predict the progress of lesions, as ESCC patients with diploid cells lived longer than ones with polyploidy. One study in 2001 showed that the progression rate from oral dysplasia to invasive or carcinoma, based on the detection of DNA aneuploidy was only 10% after 1 year but increased significantly, to 90%, after 5 years. DNA-ICM has been used as a diagnostic tool and aneuploidy tended to correlate with progression to invasive SCC. Esophageal squamous cell carcinogenesis is thought to be a multi-step process, influenced by multiple factors. Changes in DNA ploidy occurring in human tumors are shown to be a global reflection of the chromosomal and subchromosomal genetic changes which play a key role in tumor development and progression. It had been indicated that the aneuploid cell is important in the early stage of carcinogenesis. Therefore, we believe that aneuploid cells as a biomarker can be detected by DNA-ICM, which not only may be used for screening precancerous lesions of ESCC, but also for clinical diagnoses, prognostic evaluation and, in particular, patient follow-up and management after screening.

In summary, this is the first population-based study to focus on the relationship between the alteration in DNA content and ESCC and its precancerous lesions. We found that higher grade esophageal precancerous lesions had a higher proportion of aneuploid cells. Confirmed by pathological diagnoses from endoscopic biopsy, DNA-ICM had higher sensitivity, based on moderate dysplasia or worse as threshold, in ESCC screening than liquid-based cytology. Thus, it is possible to use DNA-ICM as the primary screening method in ESCC in high-risk areas.
of China. Further larger sample studies are under consideration.

ACKNOWLEDGMENTS

We thank the staff of Feicheng People’s Hospital, Feicheng, Shandong Province and Linzhou Cancer Hospital, Linzhou, Henan Province, China, for their cooperation with esophageal specimen and data collection.

COMMENTS

Background

Several screening methods have limitation in screening esophageal squamous cell carcinoma (ESCC) and precancerous lesions. Thus, it is necessary to explore a simple, objective, sensitive method as a primary screening method.

Research frontiers

In several previous studies, researchers obtained specimens from surgical tissue and endoscopic biopsy. They analyzed the prognostic value of DNA-ploidy in the progression of ESCC and predicted the prognosis of ESCC. These studies were not population-based studies, but small sample clinical studies. DNA image cytometry (DNA-ICM) has been used as a screening method in cervical cancer, which showed that the sensitivity of DNA-ICM was higher than that of cytology.

Innovations and breakthroughs

This is the first population-based study to explore DNA-image analysis technology as a screening method in ESCC. Our study is also the first study using cytological sampling for DNA-ICM with Feulgen staining by inflatable balloon. According to our results, the specificities of DNA-ICM were higher than those of liquid-based cytology based for moderate dysplasia or worse.

Applications

It is possible to use DNA-ICM as a primary method in ESCC and precancerous lesions according to our results. Further larger sample studies are under consideration to verify our results.

Terminology

The diploid cell is normal according to diagnosis by DNA imaging, which means it has a normal DNA content. The aneuploid cell has abnormal DNA content.

Peer review

The authors address an important issue considering the shortage of experienced cytologists, pathologists, and endoscopic doctors in rural high-risk areas.

REFERENCES

1. Wang GQ, Jiao GG, Chang FB, Fang WH, Song JX, Lu N, Lin DM, Xie YQ, Yang L. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. Ann Thorac Surg 2004; 77: 1740-1744
2. Shu YJ. Cytopathology of the esophagus. An overview of esophageal cytopathology in China. Acta Cytol 1983; 27: 7-16
3. Shen O, Liu SF, Dawsey SM, Cao J, Zhou B, Wang D, Li GY, Zhao ZZ, Li GY, Taylor PR. Cytologic screening for esophageal cancer: results from 12,877 subjects from a high-risk population in China. Further larger sample studies are under consideration to verify our results.

4. Dawsey SM, Shen Q, Nieberg RK, Liu SF, Dawsey SM, Cao J, Zhou B, Wang D, Li GY, Zhao ZZ, Li GY, Taylor PR. Cytologic screening for esophageal cancer: results from 12,877 subjects from a high-risk population in China. Further larger sample studies are under consideration to verify our results.

5. Roh T, Liu SF, Dawsey SM, Zhou B, Copeland C, Wang GQ, Solomon D, Baker SG, Giffen CA, Taylor PR. Cytologic detection of esophageal squamous cell carcinoma and precancerous lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. Cancer Epidemiol Biomarkers Prev 1997; 6: 121-130
6. Pan QJ, Roth MJ, Guo HQ, Kochman ML, Wang GQ, Henry M, Wei WQ, Giffen CA, Lu N, Abnet CC, Hao CQ, Taylor PR, Qiao YL, Dawsey SM. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Linxian, China. Acta Cytol 2008; 52: 14-23
7. Qin DX, Wang GQ, Zuo JH, Zhang XH, Yuan FL, Li MS, Wu CR, Cao J, Wu CR. Screening of esophageal and gastric cancer by occult blood bead detector. Cancer 1993; 71: 216-218
8. Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, Lewin KJ, Roth MJ, Cao J, Taylor PR. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer 1998; 83: 220-231
9. Guo HQ, Wei WQ, Lu N, Cao J, Li ZL, Wang NP, Wang GQ, Pan QJ, Qiao YL. [Liquid-based cytology for esophageal carcinoma screening]. Ai Zheng 2009; 28: 1243-1247
10. Velmans JA, Bot FJ, Huyven FC, Ramaekers FC, Manji J, Hoppman AH. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol 2000; 18: 1644-1651
11. Doki Y, Shiozaki H, Tahara H, Kobayashi K, Miyata M, Okita T, Hiramatsu K, Mori T. Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement. Cancer 1993; 72: 1813-1818
12. Rötger D, Pfister S, Stöille K, Wahl W, Jugenheimer M, Effenberger-Kim O, Vinth J, Jungunger T. DNA image cytometry. A prognostic tool in squamous cell carcinoma of the esophagus? Cancer 1991; 67: 2290-2294
13. Blunt SA, Ballini JP, Caron CT, Fontolliet C, Monnier P, Mairini NR. Evolution of DNA ploidy during squamous cell carcinogenesis in the esophagus. Dis Esophagus 2001; 14: 178-184
14. Tong H, Shen R, Wang Z, Kan Y, Wang Y, Li F, Wang F, Yang J, Guo X. DNA ploidy cytometry testing for cervical cancer screening in China (DNAIC Trial): a prospective randomized, controlled trial. Clin Cancer Res 2009; 15: 6438-6445
15. Solomon D. The Bethesda System for reporting cervical/vaginal cytologic diagnosis: an overview. Int J Gynecol Pathol 1991; 10: 323-325
16. Tezcan A, Garner DM, Lam P. Analysis of thionin, gallocaclin and hematoxylin for automated quantitative image cytometry of cervical samples. 8th Annual Meeting, Clinical Application of cytometry, 1993; Charleston, SC: Springer, 1993; 15-18
17. Guillaud M, Benedet JL, Cantor SB, Stuerkel G, Follen M, MacAulay C. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. Cancer 2006; 107: 309-318
18. Haroske G, Giroud F, Reith A, Böcking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998; 17: 189-200
19. Giroud F, Haroske G, Reith A, Böcking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations for quality assurance. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998; 17: 201-208
20. Singh M, Mehrotra S, Kalra N, Singh U, Shukla Y. Correlation of DNA ploidy with progression of cervical cancer. J Cancer Epidemiol 2008; 2008: 298495
21. Diwakar N, Sperandio M, Sherriff M, Brown A, Odell EW. Heterogeneity, histological features and DNA ploidy in oral carcinoma by image-based analysis. Oral Oncol 2005; 41: 416-422
22. Krause FS, Feil G, Bichler KH, Schrott KM, Akcetin ZY, Engenhauser DG. Heterogeneity in prostate cancer: prostate
specific antigen (PSA) and DNA cytophotometry. *Anticancer Res* 2005; 25: 1783-1785

23 **Razak IA**, Usman A, Fun HK, Yamin BM, Keat GW. Dichlorobis(trimethylenethiourea-kappaS)antimony(III) chloride. *Acta Crystallogr C* 2002; 58: m122-m123

24 **Klimstra DS**. Pathologic prognostic factors in esophageal carcinoma. *Semin Oncol* 1994; 21: 425-430

25 **Matsuura H**, Sugimachi K, Ueo H, Kuwano H, Koga Y, Okamura T. Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA analysis. *Cancer* 1986; 57: 1810-1814

26 **Böcking A**, Nguyen VQ. Diagnostic and prognostic use of DNA image cytometry in cervical squamous intraepithelial lesions and invasive carcinoma. *Cancer* 2004; 102: 41-54

27 **Kashyap V**, Das BC. DNA aneuploidy and infection of human papillomavirus type 16 in preneoplastic lesions of the uterine cervix: correlation with progression to malignancy. *Cancer Lett* 1998; 123: 47-52

28 **Lengauer C**, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998; 396: 643-649

29 **Shackney SE**, Shankey TV. Common patterns of genetic evolution in human solid tumors. *Cytometry* 1997; 29: 1-27

**S- Editor** Tian L. **L- Editor** Cant MR. **E- Editor** Zhang DN